Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 28, 2026; 32(44): 121290
Published online Nov 28, 2026. doi: 10.3748/wjg.121290
Published online Nov 28, 2026. doi: 10.3748/wjg.121290
Advanced therapies in patients with inflammatory bowel disease: A nationwide population-based cohort study
Hyoung Il Choi, Jung Rock Moon, Jae Myung Cha, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Seoul 05278, South Korea
Sun Hwa Lee, Department of Biostatistics, Samsung Medical Center, Seoul 06351, South Korea
Author contributions: Cha JM conceived and design the research plan ideas; Choi HI, Moon JR, Lee SH, and Cha JM performed data acquisition and interpretation of the study; Lee SH and Cha JM analyzed the statistical data of the study; Choi HI and Cha JM drafted and revised the manuscript; all the authors approved the final manuscript.
AI contribution statement: Portions of this manuscript were edited using ChatGPT to check specific English expressions for language refinement and proofreading. AI tools were not used to generate original scientific data, perform independent analyses, or draw scientific conclusions. The authors carefully review and verified all AI-assisted outputs and take full responsibility for the integrity and scientific content of the manuscript.
Supported by BongHwa Scholarship Foundation to the Korean Association for the Study of Intestinal Diseases for 2024.
Institutional review board statement: The study protocol was approved by the Institutional Review Board of Kyung Hee University Hospital in Gangdong (KHNMC IRB No. 2024-05-011).
Informed consent statement: Because all patient data in the Health Insurance Review and Assessment claims database are anonymized, informed consent was not required.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
STROBE statement: The authors have read the STROBE Statement—a checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-a checklist of items.
Data sharing statement: The data reported in this study are available from the corresponding author upon reasonable request.
Corresponding author: Jae Myung Cha, MD, Doctor, Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, 892 Dongnam-ro, Gangdong-gu, Seoul 05278, South Korea. drcha@khu.ac.kr
Received: March 23, 2026
Revised: June 12, 2026
Accepted: July 2, 2026
Published online: November 28, 2026
Processing time: 193 Days and 19.4 Hours
Revised: June 12, 2026
Accepted: July 2, 2026
Published online: November 28, 2026
Processing time: 193 Days and 19.4 Hours
Core Tip
Core Tip: This nationwide Korean study demonstrates that advanced therapy use for inflammatory bowel disease shows distinct patterns between Crohn’s disease and ulcerative colitis. Anti-tumor necrosis factor agents, particularly infliximab, are the most common first-line treatments, with earlier initiation and longer persistence in Crohn’s disease. In contrast, vedolizumab is more frequently used for ulcerative colitis, and ustekinumab more commonly used for Crohn’s disease. Overall, treatment sequencing and durability differed significantly according to disease subtype, highlighting the importance of tailored, disease-specific therapeutic strategies in real-world clinical practice.